APL Screen

Molecular Haematology

---

Description

The chromosomal translocation t(15;17) has been shown to be important in clinical practice. This aberration is specific for acute promyelocytic leukaemia, and indicates the specific treatment by the differentiative agent all-trans retinoic acid (ATRA). The molecular consequence of this translocation is PML-RARa gene fusion. The are 3 breakpoint cluster regions, one at the 5'end and 2 at the 3' end of the PML gene, requiring amplification of 2 separate PCR's with different primers and Mg2+ concentrations. The polymerase chain reaction (PCR) is a rapid and powerful method for detection of cDNA after reverse transcription of mRNA. PCR efficiently detects the chromosomal translocation t(15;17) and may also be used to detect minimal residual disease.

---

Indications

Performed in cases suspected of having acute promyelocytic leukaemia. For AML see AML screen.

---

Sample Type

5ml EDTA blood or bone marrow, less than 48 hrs old�

---

Turnaround Time

Within 4 weeks

---

Testing Frequency

As required�

---

External Notes

�Level of detection 1 leukaemic cell in 103 normal cells.

---

Please note: the above information is subject to change and we endeavour to keep this website up to date wherever necessary.